Abstract: The present application is directed to methods for producing a population of cells comprising y5 T cells. The present application is also directed to, e.g, compositions FIG. 1B useful for such production methods, populations of produced cells, and methods of use thereof.

Abstract: The present application provides methods and compositions for treating cancers (such as solid tumors) using engineered immune cells encoding a sialidase and a chimeric immune receptor. In some embodiments, the engineered immune cell is a CAR-T, CAR-NK, CAR-M, or CAR-NKT cell. In some embodiments, the sialidase is an Actinomyces viscosus sialidase or a derivative thereof, such as DAS 181. In some embodiments, the methods and compositions provided herein reduce sialylation of tumor cells and/or immune cells.

Abstract: The present application provides methods and compositions for treating cancers (such as solid tumors) using a recombinant oncolytic virus encoding a sialidase. In some embodiments, the oncolytic virus further encodes one or more other heterologous proteins. In some embodiments, the recombinant oncolytic virus is delivered via an engineered immune cell. In some embodiments, the present application provides methods and compositions for treating cancers using a recombinant oncolytic vims encoding a sialidase or another heterologous protein and an engineered immune cell (e.g., a CAR-T, CAR-NK, or CAR-NKT cell) expressing a chimeric receptor capable of binding to the sialidase or other heterologous protein.

Abstract: Recombinant oncolytic viruses for expression of sialidase and their use in the treatment of cancer, particularly solid tumors, are described.

Abstract: The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant,DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HTLV-III.

Abstract: Antigenic epitopes associated with the extracellular segment of the domain which anchors immunoglobulins to the B cell membrane are disclosed. For IgA, the epitopes are present on IgA-bearing B cells but not the secreted, soluble form of IgA. The epitope can be exploited for therapy and prophylacsis. For example, antibodies specific for the epitopes associated with the anchor and peptide encompassing the epitope domain of IgA can be used to increase secretory IgA production for the purposes of treating patients susceptible with infectious diseases and IgE-mediated allergic diseases.